Miaoyue iMDT Files IPO Prospectus: Profitable Within Six Months, Building a Standardized, Full-Cycle Oncology Service Platform from MDT

Multidisciplinary Team (MDT) refers to a diagnosis and treatment model in which medical experts from different disciplines are brought together to develop standardized, individualized, and continuous treatment plans for patients in a planned manner, which are then implemented by relevant specialties either independently or through multidisciplinary collaboration.

MDT, which originated in the 1990s, has now become the mainstream approach to cancer diagnosis and treatment in Western countries. France and the United Kingdom elevated MDT to a legal requirement in 2002 and 2007, respectively.

Compared with single-discipline diagnosis and treatment models, MDT can better avoid missed diagnoses, misdiagnoses, and inappropriate treatments.

MDT not only leverages the collective expertise of multiple disciplines to provide patients with optimal treatment plans, but also serves as a high-quality platform for enhancing standardized oncology diagnosis and treatment capabilities and academic standards, optimizing resource allocation, and addressing regional disparities in healthcare quality under the policy framework of tiered diagnosis and treatment. With the rise and growing popularity of internet-based healthcare, the advantages of “Internet + Multidisciplinary Diagnosis and Treatment” are becoming increasingly prominent.

The founder of iMDT was first exposed to Multidisciplinary Team (MDT) care upon entering the healthcare industry in 2007 and has conducted in-depth research and analysis on MDT in recent years. Through discussions with domestic and international experts and visits to tertiary hospitals, he recognized that MDT holds significant development potential in China; however, it remains in the early stages of market development within the actual clinical environment.

Driven by the substantial business opportunities and growth potential in the healthcare industry, combined with years of clinical experience and accumulated resources from hospitals and pharmaceutical companies, the founding team of Miaoyue made the decision to embark on their entrepreneurial journey. In December 2019, Miaoyue iMDT was officially incorporated as an internet healthcare company specializing in the field of oncology.

Currently, the hospital coverage rate of MDT in China is very low, at only 16%, which is significantly lower than the 80% application rate in Western countries. There are many reasons for this, and the iMDT team categorizes them mainly into the following types:

Economic Reasons:Convening experts from various disciplines at fixed times and locations for multidisciplinary tumor diagnosis, treatment, and communication is inefficient and incurs high economic costs. Due to objective constraints on hospital service pricing, this approach is economically unviable for both hospitals and physicians.

Reasons for Clinical Pathway:The lack of clinical pathways and specialized tools for MDT in China is one of the key factors contributing to the low adoption rate of the MDT diagnosis and treatment model in Chinese hospitals.

Reasons for Departmental Competition:Currently, some hospitals exhibit disordered admission practices for oncology patients. As patient diagnosis and treatment outcomes are linked to the financial interests of departments and physicians, certain departments and doctors lack the incentive to implement the Multidisciplinary Team (MDT) care model.

Addressing these pain points, the iMDT team has adopted a patient-centered, evidence-based approach to establish multidisciplinary treatment (MDT) decision-making models for various cancer types. By transitioning offline MDT consultations to an online platform and leveraging internet-based MDT services, dynamic big data on case histories, and academic support, iMDT creates value for both patients and physicians.

When building its team, iMDT gave full consideration to the characteristics of both the internet and multidisciplinary teams (MDTs), establishing a typical “healthcare + internet” configuration. This structure comprises three complementary teams with specialized expertise: an internet healthcare technology, product, and operations team; a team of experts with extensive experience in clinical oncology diagnosis and treatment as well as MDT services; and a professional academic support team. Core members include clinical specialists from China’s top oncology hospitals, seasoned practitioners in internet healthcare, and senior executives from renowned pharmaceutical companies specializing in oncology.

“From connecting information and people, to doctor-patient connections primarily based on light consultations, and then to internet hospitals marked by online follow-up visits and electronic prescriptions, internet healthcare has initially formed a service model but remains in its early stages,” stated iMDT. “On one hand, the needs of doctors and patients vary significantly across different departments, making it difficult to achieve depth while striving for comprehensiveness. On the other hand, for serious conditions such as cancer, the services provided by internet healthcare to both doctors and patients remain limited and superficial.”

"From the perspectives of both clinical experts and internet healthcare practitioners, meeting the deeper needs of doctors and patients within specialized fields is an inevitable choice for the next stage of internet healthcare."

“Cancer patients’ needs form a chain of demands, with each link representing an essential requirement; only standardized treatment throughout the entire disease course and long-term standardized services can deliver maximum value.” Based on this understanding, iMDT has developed three core capabilities:

First is the multidisciplinary team (MDT) decision-making model.To address the high costs and operational challenges associated with offline multidisciplinary team (MDT) coordination, iMDT has collaborated with established hospital MDT teams to develop a multidisciplinary diagnostic and treatment decision-making model. This model enables specialists from various disciplines to make decisions quickly and conveniently, thereby maximizing team efficiency.

Next is the dynamic big data of medical cases.iMDT has collaborated with clinical oncology experts to establish data standards, capturing clinical diagnosis and treatment data—including patient case histories, imaging, and treatment courses—through online multidisciplinary consultations, while ensuring dynamic data updates through follow-ups and phased MDT sessions.

iMDT stated, “Dynamic big data on medical cases not only enhances communication between doctors and patients and improves the efficiency of multidisciplinary teams (MDTs). As the volume of data samples continues to grow, it can also provide robust support for the iteration of diagnostic and treatment decision-making models, as well as for strengthening the evidence base and standardization of clinical decisions, thereby serving both clinical practice and scientific research.”

Finally, academic services.The most fundamental challenges in oncology care remain insufficient resources, uneven distribution, and inadequate standardization. iMDT has established a multidisciplinary team (MDT) collaboration network and an academic exchange network between top-tier regional hospitals and primary care institutions, facilitating the vertical integration of medical resources and extending them to the grassroots level. Meanwhile, by collaborating with senior experts across various specialties to create dedicated academic columns, iMDT helps oncologists stay at the forefront of academic advancements and provides a platform for scholarly exchange.

Leveraging these three core capabilities, iMDT will officially launch its Internet-based Intelligent Multidisciplinary Diagnosis and Treatment Tool (APP) and its MDT-based Full-Scenario Online Academic Service Tool (PC) in June.

Miaoyue iMDT’s product suite supports intelligent text-and-image-based MDT, video-based MDT, and inter-hospital MDT. By leveraging a case database to structure clinical case data, the platform enables multidisciplinary experts to make efficient decisions with the assistance of decision-support models, without requiring simultaneous online presence, ultimately generating a unified decision report. Patients can access services from leading oncology specialists and MDT teams at any time through Miaoyue iMDT, while their attending physicians coordinate between the patients and the MDT team to deliver clinical treatment and provide periodic feedback on therapeutic outcomes.

Meanwhile, the iMDT expert team can leverage its PC-based platform to conduct online academic and surgical exchanges. By simultaneously advancing diagnostic and therapeutic tools alongside standardized clinical services, iMDT aims to lay the foundation for standardized whole-course care by strengthening two critical links: clinical decision-making and treatment standardization.

Discipline-based education is a crucial approach to enhancing diagnostic and therapeutic standards. iMDT has launched inter-hospital MDT practical training and the National Colorectal Cancer MDT Competition across multiple provinces in China. By providing standardized MDT diagnosis and treatment education services—through case-based MDT collaborations between top-tier regional hospitals and primary care institutions, as well as competition-format MDT activities—iMDT aims to establish standardized MDT clinical pathways, improve diagnostic and therapeutic capabilities, and effectively address imbalances in medical care quality across different regions.

During the pandemic, iMDT collaborated with MDT teams and renowned experts from numerous Grade-A tertiary hospitals—including Sun Yat-sen University Cancer Center, The Affiliated Tumor Hospital of Guangxi Medical University, Hunan Cancer Hospital, Yunnan Cancer Hospital, Peking Union Medical College Hospital, Nanfang Hospital, and the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences—to host over 60 public welfare live-streaming sessions. These sessions provided multidisciplinary consultations, case interpretations, academic exchanges, and surgical discussions for cancer patients and physicians.

According to iMDT, the company has established partnerships with several renowned Grade 3A hospitals and oncology pharmaceutical companies. Operationally, it leverages its internet hospital platform to integrate multidisciplinary diagnosis and treatment, dynamic case data, online follow-up consultations, electronic prescriptions, and pharmaceutical and academic services, thereby initially establishing a closed-loop system for standardized, full-course oncology care. Notably, within just six months of its establishment, iMDT has achieved contract values sufficient to reach profitability.

In the long term, iMDT plans to enter the market through Multidisciplinary Teams (MDTs) and establish a standardized service platform covering the entire oncology care continuum. It aims to provide patients with comprehensive, standardized management services—including diagnosis, treatment, and medications—through an integrated online-offline model, while offering doctors and pharmaceutical companies comprehensive services encompassing data, academic support, scientific research, and marketing.

To expand market scale and explore business models for the consumer end, iMDT will launch a financing plan.